Depressive Disorder, Major
Pipeline by Development Stage
Drug Modality Breakdown
On Market (6)
Approved therapies currently available
Competitive Landscape
33 companies ranked by most advanced pipeline stage
+3 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 20,243 patients across 50 trials
Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder
Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features
Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects
Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects
Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.
Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance
Switching to Duloxetine in Patients With Depression
Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.
Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression
Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program
Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
Sexual Functioning Study With Antidepressants
Study of Medication and Placebo Response in Major Depression
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.
Molecular Mechanisms of Type 2 Diabetes Mellitus
A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression
Estrogen and Perimenopausal Depression
Safety Study of Pioglitazone Compared To Glyburide on Liver Function
Study Evaluating Venlafaxine ER in Recurrent Depression
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)
Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)
Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)
Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)
Study of Rapastinel as Monotherapy in Patients With MDD
Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age
Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder
A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
A Safety Study in Participants With Major Depressive Disorder
Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes
Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD
Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.
Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.
Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic Syndrome in Subjects With Type 2 Diabetes
Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.
A Local Register Study For Major Depression Of Paroxetine Controlled Release
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women
Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects
Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women
Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.